Merriman Curhan Ford initiates coverage on Avanir Pharmaceuticals (Nasdaq: AVNR) with a Buy rating. Price target range of $4-7.

Merriman ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE